PDE4D7 Gene Profiling for Radiotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the response of prostate cancer patients to radiotherapy are inadequate, leading to ineffective treatments and significant side effects, with a need for better predictive tools to optimize therapy selection and reduce costs.
Innovation Solution
A method involving the determination of gene expression profiles for PDE4D7 correlated genes such as ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2 in biological samples to predict radiotherapy response, allowing for personalized therapy recommendations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiotherapy is administered to prostate cancer patients, then cancer recurrence is reduced, but treatment effectiveness varies significantly and side effects occur
Solution Approach 1:
The patent performs gene expression profiling before radiotherapy to predict treatment response in advance. By analyzing the expression levels of specific genes (including PDE4D7 and correlated genes), the method determines which patients are likely to respond well to radiotherapy before treatment begins, allowing for personalized therapy decisions that improve overall treatment effectiveness while avoiding unnecessary treatments for non-responders.
2Measurement precision
If gene expression profiling is performed to predict radiotherapy response, then treatment prediction accuracy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts and focuses on a specific subset of genes correlated with PDE4D7 expression that are most predictive of radiotherapy response. Rather than analyzing the entire genome or all differentially expressed genes, the invention identifies and measures only the key correlated genes (such as ABCC5, CUX2, KIAA1549, and others), simplifying the diagnostic process while maintaining high prediction accuracy.
3Loss of energy
If personalized therapy recommendations are provided based on gene expression, then unnecessary treatments are reduced, but cost of testing increases
Solution Approach 1:
The patent changes the parameter being measured from general clinical markers to specific gene expression levels. By quantifying the expression levels of PDE4D7-correlated genes and comparing them against established thresholds, the method provides an objective, measurable parameter that directly predicts radiotherapy response. This allows for cost-effective decision-making by identifying non-responders who would benefit from alternative treatments, thereby reducing the overall resource waste from ineffective therapies.
Data Source
AI summary
The invention relates to a method of predicting a response of a prostate cancer subject to radiotherapy, comprising determining or receiving the result of a determination of a gene expression profile for each of two or more PDE4D7 correlated genes selected from the group consisting of: ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2, said gene expression profiles being determined in a biological sample obtained from the subject, and determining the 5 prediction of the radiotherapy response based on the gen expression profiles for the two or more PDE4D7 correlated genes.